These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 15716665)
21. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656 [TBL] [Abstract][Full Text] [Related]
22. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Benjamin JL; Hedin CR; Koutsoumpas A; Ng SC; McCarthy NE; Hart AL; Kamm MA; Sanderson JD; Knight SC; Forbes A; Stagg AJ; Whelan K; Lindsay JO Gut; 2011 Jul; 60(7):923-9. PubMed ID: 21262918 [TBL] [Abstract][Full Text] [Related]
23. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gorard DA; Hunt JB; Payne-James JJ; Palmer KR; Rees RG; Clark ML; Farthing MJ; Misiewicz JJ; Silk DB Gut; 1993 Sep; 34(9):1198-202. PubMed ID: 8406153 [TBL] [Abstract][Full Text] [Related]
24. Natalizumab for active Crohn's disease. Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S; N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039 [TBL] [Abstract][Full Text] [Related]
25. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Stack WA; Mann SD; Roy AJ; Heath P; Sopwith M; Freeman J; Holmes G; Long R; Forbes A; Kamm MA Lancet; 1997 Feb; 349(9051):521-4. PubMed ID: 9048788 [TBL] [Abstract][Full Text] [Related]
26. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. Ruuska T; Savilahti E; Mäki M; Ormälä T; Visakorpi JK J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):175-80. PubMed ID: 7815239 [TBL] [Abstract][Full Text] [Related]
27. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878 [TBL] [Abstract][Full Text] [Related]
28. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Hanauer S Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400 [TBL] [Abstract][Full Text] [Related]
29. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease. Okada M; Yao T; Yamamoto T; Takenaka K; Imamura K; Maeda K; Fujita K Hepatogastroenterology; 1990 Feb; 37(1):72-80. PubMed ID: 2179093 [TBL] [Abstract][Full Text] [Related]
30. A controlled double blind study of azathioprine in the management of Crohn's disease. Candy S; Wright J; Gerber M; Adams G; Gerig M; Goodman R Gut; 1995 Nov; 37(5):674-8. PubMed ID: 8549944 [TBL] [Abstract][Full Text] [Related]
31. Budesonide for induction of remission in Crohn's disease. Otley A; Steinhart AH Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274 [TBL] [Abstract][Full Text] [Related]
34. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Verma S; Brown S; Kirkwood B; Giaffer MH Am J Gastroenterol; 2000 Mar; 95(3):735-9. PubMed ID: 10710067 [TBL] [Abstract][Full Text] [Related]
35. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. O'Moráin C; Segal AW; Levi AJ Br Med J (Clin Res Ed); 1984 Jun; 288(6434):1859-62. PubMed ID: 6428577 [TBL] [Abstract][Full Text] [Related]
36. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W; Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677 [TBL] [Abstract][Full Text] [Related]
37. Emulsifiers Impact Colonic Length in Mice and Emulsifier Restriction is Feasible in People with Crohn's Disease. Sandall AM; Cox SR; Lindsay JO; Gewirtz AT; Chassaing B; Rossi M; Whelan K Nutrients; 2020 Sep; 12(9):. PubMed ID: 32942699 [TBL] [Abstract][Full Text] [Related]
38. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Carty E; Rampton DS; Schneider H; Rutgeerts P; Wright JP Aliment Pharmacol Ther; 2001 Sep; 15(9):1323-9. PubMed ID: 11552902 [TBL] [Abstract][Full Text] [Related]
39. Methotrexate for induction of remission in refractory Crohn's disease. Alfadhli AA; McDonald JW; Feagan BG Cochrane Database Syst Rev; 2003; (1):CD003459. PubMed ID: 12535475 [TBL] [Abstract][Full Text] [Related]
40. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Leiper K; Woolner J; Mullan MM; Parker T; van der Vliet M; Fear S; Rhodes JM; Hunter JO Gut; 2001 Dec; 49(6):790-4. PubMed ID: 11709513 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]